Market Overview

Mylan's Stock Is No Longer A Buy According To Analysts At Argus

Share:
Mylan's Stock Is No Longer A Buy According To Analysts At Argus

Analysts at Argus no longer hold a bullish view on Mylan N.V. (NASDAQ: MYL) after the company cut its full-year guidance and cautioned that its earnings per share will decline in 2017. The firm's Jasper Hellweg downgraded Mylan's stock rating from Buy to Hold as the stock is fairly valued at its current price of near $30 per share.

Mylan's stock has been under pressure over the past year and this weakness attracted the attention of activist investors who are looking to influence the company and reverse the weakness, Hellweg commented in a research report. While this is typically seen as a positive catalyst for the stock there are bigger issues at play that could limit upside.

On top of Mylan's revised outlook to the downside, the pharmaceutical company also has to contend with unfavorable regulatory developments, pricing pressures, and heightened competition, Hellweg continued. In fact, the core EpiPen product now faces new competition from Adamis Pharmaceuticals Corp (NASDAQ: ADMP)'s Symjepi epinephrine syringe, which received FDA approval on June 15 and will be labeled as a low-cost alternative to the Epi-Pen.

Adamis is also developing a "junior version" of Symjepi, which will also compete with Mylan's low-dose EpiPen Jr.

On top of that, Mylan is under investigation by the New York attorney general for selling EpiPens to schools in exchange for exclusive contracts. Also, Sanofi SA (ADR) (NYSE: SNY) filed an antitrust lawsuit against Mylan and alleges the company is unfairly offering discounts to insurers and pharmacy benefit managers.

Related Links:

The Prescription For Generic Drugs ETF

Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval
________
Image Credit: By Intropin - Own work, CC BY 3.0, via Wikimedia Commons

Latest Ratings for MYL

DateFirmActionFromTo
Mar 2019Morgan StanleyUpgradesEqual-WeightOverweight
Feb 2019BernsteinDowngradesOutperformMarket Perform
Jan 2019UBSDowngradesBuyNeutral

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Guidance Downgrades Health Care FDA Legal Best of Benzinga

 

Related Articles (MYL + ADMP)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
CASADA DavidsonInitiates Coverage On12.0
RCIIJefferiesMaintains22.0
DPLOMorgan StanleyMaintains8.0
QLYSSummit Insights GroupDowngrades0.0
ECACitigroupReinstates0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

A Gem Among Real Estate ETFs

The Market In 5 Minutes